Advanced 3D Cell Models for Preclinical Research: iBET Welcomes Visit and Seminar by Dr. Eckhard von Keutz

"Advanced 3D Cell Models in Preclinical Research: Context, Current State and the Path Forward"

On March 2, iBET welcomed Dr. Eckhard von Keutz, independent consultant and leading expert in drug discovery and development, for strategic discussions and an iNOVA4Health seminar on “Advanced 3D Cell Models in Preclinical Research: Context, Current State and the Path Forward”.

With more than 30 years of senior leadership experience at Bayer AG, Dr. von Keutz is widely recognized for his contributions to global preclinical and early clinical programs across multiple therapeutic areas.

His visit offered valuable perspectives on the current landscape of advanced 3D cell systems and their growing role in improving translational effectiveness in drug development.

During the seminar, Dr. von Keutz highlighted the opportunities these models present for generating human-relevant data and supporting decision-making in early research. He also reflected on how industry and regulatory bodies are approaching the integration of complementary preclinical tools, including new approach methodologies (NAMs).

iNOVA4Health Seminar delivered by Dr. Eckhard von Keutz.

The session concluded with a forward-looking view on what needs to evolve for 3D cell models to deliver broader strategic impact in the coming years.

At iBET, research in the field of Advanced Cell Models for Drug Discovery and Translational Research (Head of Lab: Catarina Brito) spans several decades, beginning with efforts in modelling disease progression and assessing the efficacy of gene therapies and immunotherapies. More recently, this work is expanding to address increasingly complex protein-based therapeutics (e.g. multispecific antibodies and antibody-drug conjugates and other advanced recombinant proteins).

Left: Dr. Eckhard von Keutz with iBET CEO Prof Paula Alves and Dr. Clive R. Wood (iBET SAB Chairman). Right: Dr. von Keutz answer to questions of the audience after his seminar.

iBET acknowledges Dr. Eckhart von Keutz for sharing his expertise and delivering such inspiring seminar.

Related news

iBET Welcomes Dr. Mark Duerkop, CEO and Co-founder of Novasign
March 30, 2026

Building synergies in Cell Therapy: iBET Hosts Dr. Lindsay Davies, NextCell Pharma CSO and QVance CEO
March 18, 2026

“Reshaping Preclinical Research Through 3D Cell Models” – Podcast Interview with Catarina Brito
January 23, 2026

Antibody-Drug Conjugates Landscape, Challenges and Opportunities: iBET Welcomes Dr. John Lambert
December 12, 2025

Emerging Innovations in Baculovirus Expression Vector System (BEVS): iBET Hosts iNOVA4Health Seminar by Dr. Imre Berger
November 19, 2025